It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Fine-tuning of insulin release from pancreatic β-cells is essential to maintain blood glucose homeostasis. Here, we report that insulin secretion is regulated by a circular RNA containing the lariat sequence of the second intron of the insulin gene. Silencing of this intronic circular RNA in pancreatic islets leads to a decrease in the expression of key components of the secretory machinery of β-cells, resulting in impaired glucose- or KCl-induced insulin release and calcium signaling. The effect of the circular RNA is exerted at the transcriptional level and involves an interaction with the RNA-binding protein TAR DNA-binding protein 43 kDa (TDP-43). The level of this circularized intron is reduced in the islets of rodent diabetes models and of type 2 diabetic patients, possibly explaining their impaired secretory capacity. The study of this and other circular RNAs helps understanding β-cell dysfunction under diabetes conditions, and the etiology of this common metabolic disorder.
Circular RNAs contribute to the regulation of β-cell specific functions. Here the authors show that a circular RNA derived from one of the introns of the insulin gene is necessary for optimal insulin secretion from pancreatic islets and that its level is reduced in the islets of diabetic subjects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 University of Lausanne, Department of Fundamental Neurosciences, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204); Department of Medicine, Weill Cornell Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
2 University of Lausanne, Department of Fundamental Neurosciences, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204)
3 University of Lausanne, Department of Computational Biology, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204)
4 Aarhus University, Interdisciplinary Nanoscience Center (iNANO) and Department of Molecular Biology and Genetics, Aarhus, Denmark (GRID:grid.7048.b) (ISNI:0000 0001 1956 2722)
5 Lund University, Islet Cell Exocytosis or Islet Pathophysiology Group, Lund University Diabetes Centre, Department of Clinical Sciences in Malmö, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
6 University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy (GRID:grid.5395.a) (ISNI:0000 0004 1757 3729)
7 UMR DIATHEC, EA 7294, Centre Européen d’Etude du Diabète, Université de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291)
8 University of Lausanne, Department of Fundamental Neurosciences, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204); University of Lausanne, Department of Biomedical Sciences, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204)